A PD-1T signature as clinical applicable biomarker in NSCLC 163 4 Table S3. Patient characteristics and treatment outcomes for training and validation cohorts. P-values were calculated by Mann-Whitney, Fisher exact or linear-by-linear association tests. P-value Training cohor t (n=41) Validation cohort (n=42) Sex P=0.51 Male, no. (%) 22 (54%) 26 (62%) Female, no. (%) 19 (46%) 16 (38%) Age (years), mean (s.d.) P=0.79 64 (9.2) 64 (9.6) Smoking (never/ex/current) P=0.39 3/32/6 6/27/9 Pack years, median (IQR) P=0.27 34 (25) 30 (35) PS, no. (%) P=0.002 0 11 (27%) 3 (7%) 1 22 (54%) 25 (60%) ≥2 8 (19%) 14 (33%) Pathology, no. (%) P=0.87 Adeno 28 (68%) 27 (64%) Squamous 9 (22%) 12 (29%) LCNEC, NSCLC-type 1 (3%) 0 (0%) NSCLC, NOS 3 (7%) 3 (7%) PD-L1 TPS, no. (%) P=0.58 Negative 22 (54%) 24 (57%) Positive 1-50% 10 (24%) 7 (17%) Positive ≥50% 9 (22%) 9 (21%) Unknown 0 (0%) 2 (5%) Brain metastases, no. (%) P=0.6028 10 (24%) 8 (19%) Treatment, no. (%) Nivolumab 41 (100%) 42 (100%) Line of treatment, no (%) P=0.62 2 32 (78%) 30 (71%) >2 9 (22%) 12 (29%) Best Overall Response P=0.63 CR 3 (7%) 2 (5%) PR 9 (22%) 5 (12%) SD 4 (10%) 5 (12%) PD 25 (61%) 30 (71%) DC ≥12 months P=0.12 12 (29%) 6 (14%) ≥6 months P=0.63 13 (32%) 11 (26%) s.d., standard deviation; IQR, interquartile range; PS, Performance Score, based on the European Cooperative Oncology group (ECOG) performance status score. This is a score ranging from 0 to 5, where 0 indicates no symptoms, 1 indicates mild symptoms and above 1 indicates greater disability; LCNEC NSCLC type, large cell neuroendocrine carcinoma nonsmall cell lung cancer type; NOS, not otherwise specified; KRAS, Kirsten Rat Sarcoma viral oncogene; PD-L1, programmed death ligand 1; TPS, tumor proportion score; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DC, disease control.
RkJQdWJsaXNoZXIy MTk4NDMw